Sarepta Therapeutics Inc (SRPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sarepta Therapeutics Inc (SRPT) has a cash flow conversion efficiency ratio of -0.135x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-202.68 Million) by net assets ($1.51 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Sarepta Therapeutics Inc's balance sheet to measure how much of total assets are equity-financed.
Sarepta Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Sarepta Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Sarepta Therapeutics Inc (SRPT) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Sarepta Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sarepta Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hammond Power Solutions Inc
TO:HPS-A
|
0.031x |
|
Shenzhen Xinyichang Technology Co. Ltd. A
SHG:688383
|
0.019x |
|
Dongsuh
KO:026960
|
0.006x |
|
Guangdong Marubi Biotechnology Co
SHG:603983
|
0.012x |
|
Ral Yatirim Holding AS
IS:RALYH
|
0.230x |
|
Burckhardt Compression
SW:BCHN
|
0.100x |
|
Hainan Haide Industry Co Ltd
SHE:000567
|
-0.099x |
|
Jiangsu Changfa Refrigeration Co Ltd
SHE:002413
|
0.000x |
Annual Cash Flow Conversion Efficiency for Sarepta Therapeutics Inc (1995–2025)
The table below shows the annual cash flow conversion efficiency of Sarepta Therapeutics Inc from 1995 to 2025. For the full company profile with market capitalisation and key ratios, see Sarepta Therapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.14 Billion | $-205.48 Million | -0.180x | -33.74% |
| 2024-12-31 | $1.53 Billion | $-205.79 Million | -0.135x | +76.90% |
| 2023-12-31 | $859.34 Million | $-500.99 Million | -0.583x | +31.02% |
| 2022-12-31 | $384.95 Million | $-325.35 Million | -0.845x | -76.98% |
| 2021-12-31 | $928.01 Million | $-443.17 Million | -0.478x | -438.51% |
| 2020-12-31 | $761.76 Million | $107.47 Million | 0.141x | +125.29% |
| 2019-12-31 | $818.19 Million | $-456.46 Million | -0.558x | -48.18% |
| 2018-12-31 | $1.03 Billion | $-388.66 Million | -0.377x | -28.08% |
| 2017-12-31 | $789.22 Million | $-232.00 Million | -0.294x | +59.74% |
| 2016-12-31 | $336.69 Million | $-245.82 Million | -0.730x | +7.02% |
| 2015-12-31 | $190.35 Million | $-149.47 Million | -0.785x | -51.29% |
| 2014-12-31 | $247.65 Million | $-128.54 Million | -0.519x | -98.31% |
| 2013-12-31 | $247.19 Million | $-64.69 Million | -0.262x | -9.01% |
| 2012-12-31 | $123.68 Million | $-29.69 Million | -0.240x | +68.55% |
| 2011-12-31 | $31.02 Million | $-23.68 Million | -0.763x | -114.14% |
| 2010-12-31 | $-2.82 Million | $-15.21 Million | 5.399x | +1549.76% |
| 2009-12-31 | $23.63 Million | $-8.80 Million | -0.372x | +52.52% |
| 2008-12-31 | $15.73 Million | $-12.34 Million | -0.784x | +16.15% |
| 2007-12-31 | $26.38 Million | $-24.68 Million | -0.935x | -71.13% |
| 2006-12-31 | $37.71 Million | $-20.61 Million | -0.547x | -99.95% |
| 2005-12-31 | $53.66 Million | $-14.67 Million | -0.273x | +69.80% |
| 2004-12-31 | $26.27 Million | $-23.78 Million | -0.905x | -124.74% |
| 2003-12-31 | $43.39 Million | $-17.48 Million | -0.403x | +53.32% |
| 2002-12-31 | $23.48 Million | $-20.26 Million | -0.863x | -105.49% |
| 2001-12-31 | $30.53 Million | $-12.82 Million | -0.420x | -53.48% |
| 2000-12-31 | $33.37 Million | $-9.13 Million | -0.274x | +57.16% |
| 1999-12-31 | $11.90 Million | $-7.60 Million | -0.639x | +14.21% |
| 1998-12-31 | $9.00 Million | $-6.70 Million | -0.744x | -354.11% |
| 1997-12-31 | $18.30 Million | $-3.00 Million | -0.164x | +91.80% |
| 1996-12-31 | $800.00K | $-1.60 Million | -2.000x | -124.72% |
| 1995-12-31 | $2.00 Million | $-1.78 Million | -0.890x | -- |
About Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 ski… Read more